Jazz Pharmaceuticals (JAZZ) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
14 Jul, 2026Executive summary
The annual general meeting (AGM) is scheduled for July 23, 2026, with several key proposals up for shareholder vote.
Shareholders of record as of May 28, 2026, are eligible to vote at the AGM.
Employees who are also shareholders are encouraged to participate in the voting process to ensure their shares are represented.
Voting matters and shareholder proposals
The board and management recommend voting "FOR" all director nominees and the other five proposals presented at the AGM.
Voting instructions were distributed via mail or electronically, with specific guidance for those using E*Trade services.
Board of directors and corporate governance
The board has nominated directors for election at the AGM and supports their approval.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Jazz Pharmaceuticals
- Oncology growth, zanidatamab expansion, and robust financials drive a strong diversified outlook.JAZZ
Morgan Stanley 24th Annual Global Healthcare Conference - Zanidatamab and EPIDIOLEX anchor a robust pipeline targeting oncology and epilepsy growth.JAZZ
Deutsche Bank 2026 Healthcare Summit - Record growth, new launches, and AI-driven strategies fuel rare disease expansion and raised outlook.JAZZ
Citigroup’s Biopharma Back to School Summit 2026 - Strong commercial execution and pipeline innovation drive robust growth and future potential.JAZZ
Wells Fargo 21st Annual Healthcare Conference - FDA approved Ziihera regimens for first-line HER2+ GEA, setting a new survival benchmark.JAZZ
FDA announcement - Q2 2026 revenue up 16% YoY to $1.21B; 2026 guidance raised on strong portfolio growth.JAZZ
Q2 2026 - Strong neuroscience growth and robust pipeline progress offset oncology headwinds, supporting 2024 outlook.JAZZ
Bank of America 2025 Healthcare Conference - Record Q3 2025 revenue, raised EPS guidance, and key FDA approvals drive future growth.JAZZ
Q3 2025 - Q1 2025 revenue steady at $898M; Chimerix closed; 2025 outlook affirmed despite headwinds.JAZZ
Q1 2025